The information within this section of the website is intended for UK Healthcare Professionals. UK Practice Managers should follow the relevant links.

Picked for heritage and experience

For hormone-responsive breast cancer

  • Approximately 60% of breast cancers amongst pre-menopausal women are oestrogen-receptor-positive12 and a proportion of these patients may benefit from gonadotropin-releasing hormone (GnRH) agonist therapy
  • This approach works by blocking the production of gonadotropins in the pituitary gland which in turn blocks the release of oestrogen (and progesterone) from the ovaries1214
  • With blocked or reduced oestrogen, the oestrogen-receptor-positive breast cancer is inhibited from growing1214

MHRA approved

  • Now, following a positive opinion by the MHRA, Prostap 3 DCS has become the only three-monthly GnRH agonist preparation for premenopausal oestrogen-receptor-positive breast cancer patients3
  • In the early breast cancer setting, GnRH agonist therapy is recommended for up to 5 years in combination with either tamoxifen or an aromatase inhibitor, therefore the convenience of three-monthly administration may make a real difference to the lives of patients3

Contact

If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. Takeda UK Ltd. Data on file, DF120604(2).
  2. Prostap SR DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
  3. Prostap 3 DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
  4. Health and Safety Executive. Health and Safety (Sharp Instruments in Healthcare) Regulations 2013. Available via: www.hse.gov.uk/pubns/hsis7.pdf (last accessed May 2019).
  5. European Agency for Safety and Health at Work. Directive 2010/32/EU – prevention from sharp injuries in the hospital and healthcare sector. Available at: www.osha.europa.eu/en/legislation/directives/council-directive-2010-32-eu-prevention-from-sharp-injuries-in-the-hospital-and-healthcare-sector (last accessed May 2019).
  6. Ogawa Y et al. J Pharm 1989;41(7):439-44.
  7. Abouelfadel Z & Crawford D. Therapeut Clin Risk Manag 2008;4(2):513-26.
  8. The Leuprolide Study Group. N Eng J Med 1984;311:1281-6.
  9. Friedman AJ et al. Fertil Steril 1987;48(4):560-4.
  10. PharmaTimes online. Takeda launces new presentation of Prostap, 2011. Available at: http://www.pharmatimes.com/news/takeda_launches_new_presentation_of_prostap_980760 (last accessed May 2019).
  11. National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and management. NICE guideline (CG175).
  12. Goel S et al. Cochrane Database Syst Rev 2009;7(4):CD004562.
  13. Cancer Research UK. Hormone therapy for cancer, June 2017. Available at: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/hormone-therapy/for-cancer (last accessed May 2019).
  14. NHS UK. Breast cancer in women – Treatment, September 2016. Available at: https://www.nhs.uk/conditions/breast-cancer/treatment/ (last accessed May 2019).
  15. Zoladex 3.6 mg. AstraZeneca UK. Summary of Product Characteristics. Available at: www.medicines.org.uk
  16. Decapeptyl SR 3 mg. Ipsen Ltd. Summary of Product Characteristics. Available at: www.medicines.org.uk

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers. If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a Practice Manager

Yes

I am a Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a
Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

Yes

I am a Healthcare Professional interested in breast cancer

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.